Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
The San Diego-based DNA synthesis firm this week announced $12.2 million in Series A funding, but has plans to expand the round.
The Boston-based synthetic biology firm said it will use the funds to grow its cell programing platform, which it will make available to startups.
In Nature this week: synthetic Escherichia coli genome with fewer codons, and more.
During the second quarter of fiscal 2019, the firm took orders for genes, libraries, and oligonucleotide pools from about 780 customers.
The Economist explores potential uses of synthetic biology to alter what proteins are produced.
In Science this week: the synthetic genetic system hachimoji, and more.
Ohio State University researchers found that a phosphorothioate-modified DNA-crRNA duplex completely blocked the function of Cas12a.
Agilent alleges that Twist CEO Emily Leproust and other employees stole trade secrets from it. A trial date has been set for Feb. 24, 2020.
The Intelligence Advanced Research Projects Activity has amassed a team to spot DNA orders that could be used in bioweapons, Bloomberg reports.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.
